Highlights
Profile claimed by owner
About
TargetingTumor Heterogeneity
At Cellyrix, we are on a mission to introduce a new modality into cancer treatment by harnessing the power of cutting-edge technologies. Tumor heterogeneity, a fundamental aspect of cancer, lies at the heart of treatment challenges such as therapy resistance, metastasis, and relapse. Leveraging breakthroughs in single-cell sequencing and artificial intelligence, we are pioneering a novel approach to unlock insights into intra-tumor heterogeneity and develop innovative cancer treatments.
Identity
| Name | Cellyrix Therapeutics |
|---|---|
| Slug | cellyrix-therapeutics |
| Type / kind | startup |
| Source _id | e9eXvyis4lQWnfOIJKVXusNJkwaG9IZqgrLXUmovdKkXBOrytviSjN |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Rehovot |
| HQ address | Rehovot, Israel |
Web & social
| https://www.linkedin.com/company/103523835 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMoleculesArtificial Intelligence
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
drug-discoverycancer-therapypharmaceuticalsdrug-developmentcancerbiotechnologyartificial-intelligence
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}